Related Experiment Video
Updated: Aug 5, 2026
Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
Published on: February 24, 2023
Modeling melanoma-immune interactions with a physiological delay incorporating dendritic cell vaccines and anti-PD-1
1School of Mathematics and Statistics, Lanzhou University, Lanzhou, 730000, PR China.
Abstract:
Malignant melanoma is an aggressive skin cancer with limited responsiveness to traditional therapies. Notably, the combination of dendritic cell (DC) vaccines with anti-programmed cell death protein 1 (anti-PD-1) therapy has shown stronger clinical potential than conventional approaches. Understanding the tumor-immune interplay is essential for optimizing melanoma immunotherapy strategies. In this paper, we formulate a melanoma-specific tumor-immune interaction model of tumor cells (TCs), DCs, and effector CD8+ T cells (ECs). A key threshold value is identified to characterize tumor growth. Using this threshold, we determine the conditions for tumor-free and tumorous equilibria, consistent with cancer immunoediting theory. Furthermore, bifurcation analysis indicates that the model exhibits oscillatory behavior under certain conditions. Sensitivity and parameter heterogeneity analyses reveal that tumor burden is mainly regulated by the intrinsic tumor growth and immune activation rate. Moreover, to better reflect physiological realism, we extend the model to a time-delayed system by incorporating a constant delay for DC-to-EC activation. Analytical and numerical results demonstrate a supercritical Hopf bifurcation at a critical delay τ0 ≈ 4.68 days, leading to stable periodic solutions. Finally, an optimal control framework is proposed to design DC vaccines and anti-PD-1 injection protocols. Compared with the constant dosing strategy, optimal control achieves enhanced tumor suppression for the same total treatment intensity. This work elucidates the dynamical mechanisms of melanoma-immune interactions and establishes a theoretical foundation for personalized combination immunotherapies.
Insights
This study models melanoma's interaction with immune cells, revealing key factors regulating tumor growth. Optimal control strategies combining dendritic cell (DC) vaccines and anti-programmed cell death protein 1 (anti-PD-1) therapy enhance tumor suppression.
Area of Science:
- Immunology
- Mathematical Oncology
- Computational Biology
Background:
- Malignant melanoma is an aggressive skin cancer with limited treatment efficacy.
- Combination therapy with dendritic cell (DC) vaccines and anti-programmed cell death protein 1 (anti-PD-1) shows promise for melanoma immunotherapy.
- Understanding tumor-immune dynamics is crucial for optimizing treatment strategies.
Purpose of the Study:
- To develop a mathematical model of melanoma tumor-immune interactions.
- To analyze the conditions for tumor eradication or persistence.
- To investigate the impact of time delays and optimal control on combination immunotherapy.
Main Methods:
- Formulation of a mathematical model incorporating tumor cells (TCs), DCs, and effector CD8+ T cells (ECs).
- Bifurcation analysis to identify model dynamics, including oscillatory behavior.
- Sensitivity analysis and extension to a time-delayed system.
- Application of optimal control theory to design DC vaccine and anti-PD-1 injection protocols.
Main Results:
- A threshold value characterizing tumor growth was identified, consistent with cancer immunoediting theory.
- The model demonstrated oscillatory dynamics and identified intrinsic tumor growth and immune activation rates as key regulators.
- A supercritical Hopf bifurcation occurred at a critical delay (τ₀ ≈ 4.68 days), leading to stable periodic solutions in the delayed system.
- Optimal control strategies achieved superior tumor suppression compared to constant dosing for equivalent treatment intensity.
Conclusions:
- The study elucidates the complex dynamical mechanisms governing melanoma-immune interactions.
- Mathematical modeling provides a theoretical foundation for developing personalized combination immunotherapies.
- Optimal control frameworks can enhance the efficacy of DC vaccines and anti-PD-1 therapy in melanoma treatment.
